Hi guys, hope you are all well. Today we are looking at Exelixis, an oncology-focused biotechnology company that focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The market cap of the firm is roughly $7 billion. What drew me to looking into this company was its cash and cash equivalents value, a whopping $1.2 billion, giving it an almost 20% cash to market cap valuation. The company is forecasted to grow by 40% this year and has absolutely no debt. The P/E is high at a level of 63 however I am not concerned at all by this figure due to the fact that EPS is forecasted to grow by ten fold in the next 3-5 years. From my wave analysis, we can see that the stock consolidated nicely to form its wave 2 and is now in the approach of starting its Wave 3. This is in 1 week time scales, so I do not expect this to be a short term trade. Nevertheless, this really is a fantastic opportunity to possibly triple your investment in the next 2-3 years and I am already positioned in the stock. This is not investment advice, so please do your own due diligence before making any decisions. I hope this is helpful
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。